
    primary, 8-week efficacy endpoint not achieved. no additional benefit for subjects receiving a
    corticosteroid together with an intravitreal anti-vegf agent.
  
['macular edema', 'retinal vein occlusion']
['suprachoroidal cls-ta', 'suprachoroidal sham', 'ivt aflibercept']

        Inclusion Criteria:

          -  Has a clinical diagnosis of RVO in the study eye

          -  Has a CST of ≥ 300 µm in the study eye

          -  Has an ETDRS BCVA score of ≥ 20 letters read and ≤ 70 letters read in the study eye;

          -  Is naïve to local pharmacologic treatment for RVO in the study eye;

        Exclusion Criteria:

          -  Any active ocular disease or infection in the study eye other than RVO

          -  History of glaucoma, intraocular pressure > 21 mmHg or ocular hypertension requiring
             more than one medication

          -  Any uncontrolled systemic disease that, in the opinion of the Investigator, would
             preclude participation in the study

          -  Any evidence of neovascularization in the study eye
      